Stocktoria
Rapport Therapeutics, Inc. RAPP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-06-07
Chart by TradingView
2/9
Piotroski F — financial health
21.32
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$125.1M | -$83.1M | -$36.2M |
| Net income | -$111.5M | -$78.3M | -$34.8M |
| Operating cash flow | -$87.5M | -$64.8M | -$27.2M |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M |
| Total assets | $512.4M | $314.9M | $155.4M |
| Total liabilities | $27.8M | $9.5M | $14.5M |
| Shareholders' equity | $484.7M | $305.4M | -$25.6M |
| Ratios | |||
| Return on assets | -21.8% | -24.9% | -22.4% |
| Return on equity | -23.0% | -25.6% | 135.7% |
| Current ratio | 26.17 | 35.34 | 17.14 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 9,700 | $303,513 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 21.32 (safe)
- Working capital / assets 0.936
- Retained earnings / assets -0.459
- EBIT / assets -0.244
- Equity / liabilities 17.447
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002012593 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.